[{"uuid": "7995fd17-5c56-3ac3-a09f-bd9ad32e3397", "title": "Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/adicet-bio-reports-inducement-grants-230600745.html", "providerPublishTime": 1738364760, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Tf4cbxgpsAwZG2_X3nNpRw--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/09e7777ff5dce41242e428c9c5c31fdb", "width": 480, "height": 288, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/nPvskV6OOtcY_pzQRWBr8g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/09e7777ff5dce41242e428c9c5c31fdb", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACET"]}, {"uuid": "a43674cb-e8f9-3b08-ace2-e2a20872fecd", "title": "Adicet Bio to Participate in a Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/adicet-bio-participate-fireside-chat-120000750.html", "providerPublishTime": 1738152000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/YXV3OwKLJmYOQHHhwwQvaw--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/6231c8f529aa38396e5ec67f445a852a", "width": 480, "height": 288, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/moAP6l7ICiLTRmCjj32JXQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/6231c8f529aa38396e5ec67f445a852a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACET"]}, {"uuid": "92250431-5c34-32cf-bc7c-dac6b872d9f2", "title": "Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/adicet-bio-provides-corporate-highlights-211000326.html", "providerPublishTime": 1736370600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/qgteNYaahDf8cnclJACGJQ--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/560624f753cf2b0de1b2306b7ae60b61", "width": 480, "height": 288, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/tnRS6JpW1i5cywiwBIj_Vg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/560624f753cf2b0de1b2306b7ae60b61", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACET"]}, {"uuid": "4f2f74ae-3032-3d1b-800f-b09c3bde4bfe", "title": "Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/adicet-bio-reports-inducement-grant-214800519.html", "providerPublishTime": 1735681680, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/zhD7b3g5CHwFUMTTGg9tMQ--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/67d1ca1e52e888b3c94e14187ebd6318", "width": 480, "height": 288, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/gN_wpNt0_Fmd9kjo4_W7MA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/67d1ca1e52e888b3c94e14187ebd6318", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACET"]}, {"uuid": "c2ff2020-cd82-3cc8-9642-7d3cbb94bb08", "title": "Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/adicet-bio-announces-first-patient-120000866.html", "providerPublishTime": 1734609600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/U2gCb0_Nvz2zIIPCmTN9TA--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/49f0cf03f173e43dd83ce55b7c3c1a52", "width": 480, "height": 288, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/n.8uHl2OzXlX9N9HOK8XjQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/49f0cf03f173e43dd83ce55b7c3c1a52", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACET"]}, {"uuid": "4157cb60-b0bb-3b70-858f-7f1d8e1f62d2", "title": "Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/adicet-bio-appoints-julie-maltzman-120000482.html", "providerPublishTime": 1734523200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/D_og.zft9AbsCJg0VzAZcw--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/f6363d7da4f63e3f8271b2f786424898", "width": 480, "height": 288, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/lANSbnMFkR2Esv9qCim0EQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f6363d7da4f63e3f8271b2f786424898", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACET"]}, {"uuid": "fd02054d-2853-3435-8507-c56f7fd0b571", "title": "Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/adicet-reports-third-quarter-2024-210000809.html", "providerPublishTime": 1730926800, "type": "STORY", "relatedTickers": ["ACET"]}, {"uuid": "6339930d-8a1b-3b76-9c53-711890e72cca", "title": "Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/adicet-bio-nasdaq-acet-good-113352881.html", "providerPublishTime": 1731929632, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/eZ0FiSKCVDYnTK6X1bRieQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACET"]}, {"uuid": "602eb591-9710-3780-b52b-f9db9a41e2f6", "title": "Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/adicet-opens-enrollment-adi-270-210000535.html", "providerPublishTime": 1731963600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/JJqigpFV6jorjUuLk9sDkg--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/208047b7b25dbe57005c422a65638452", "width": 480, "height": 288, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Rn3TBRzAYyFFYHilcrPlhQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/208047b7b25dbe57005c422a65638452", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACET"]}, {"uuid": "e338bd91-30ff-3d7e-9ef0-993be1c71c2c", "title": "Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/adicet-bio-announces-first-lupus-120000573.html", "providerPublishTime": 1731931200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/XpX5aBn6VdM8LbAAE_bE3g--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a863b0d98611ba55695cfeb883a2aff1", "width": 480, "height": 288, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/TBK.WJj01XgQyUAVXyTS_Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/a863b0d98611ba55695cfeb883a2aff1", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACET"]}, {"uuid": "6ff9534a-2982-3ae1-b6a4-dd779a9c9769", "title": "Adicet Bio Presents Clinical Biomarker Data for Off-the-Shelf CAR T Cell Therapy in an Oral Session at the American College of Rheumatology (ACR) Convergence 2024", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/adicet-bio-presents-clinical-biomarker-140000237.html", "providerPublishTime": 1731765600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Rye59Ues0jMwXKyZll4xfA--~B/aD0yODg7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/699cc1b32c1c1113d633cc9434ab438e", "width": 480, "height": 288, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/sGyza63kbG8zGPzi83dxGA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/699cc1b32c1c1113d633cc9434ab438e", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ACET"]}, {"uuid": "1dd7838d-b528-34b5-bf0d-3596f0a670ec", "title": "Government of Canada invests in development of innovative start\u200d-\u200dups with support for Quebec's incubators and accelerators", "publisher": "CNW Group", "link": "https://finance.yahoo.com/news/government-canada-invests-development-innovative-151500447.html", "providerPublishTime": 1731424500, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/sNZvvkHQoRkYXhVkiBEscQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/cnwgroup.com/02ac3a3c32b224d642f841762b44e3ec", "width": 16, "height": 16, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Achc2a9aMTtdwQy5QWCrmw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/cnwgroup.com/02ac3a3c32b224d642f841762b44e3ec", "width": 140, "height": 140, "tag": "140x140"}]}}]